International Pharmaceutical Aerosol Consortium on Regulation & Science
The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) is an international non-profit association comprised of companies that develop, manufacture, market, and support research and development of inhaled and nasal drugs and biologics (INDBs). IPAC-RS seeks to advance the science, and especially the regulatory science, of these products by collecting and analyzing data, conducting joint research and development projects, and engaging the wider community. Representing this industry sector for more than 25 years, IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of its research through conferences, technical journals, webinars, and discussions with regulatory bodies.
IPAC-RS 2026 Nasal Innovation Forum
Wednesday-Thursday, September 16-17, 2026
This 1.5-day in-person event continued the discussions presented at the 2025 NIF and brought together industry leaders, academia, regulatory experts, and scientific pioneers, as they explored topics in: Patient Perspective (Keynote), Roadmap: From Discovery into the Clinic, Device Selection, Manufacturing Best Practices, Rapid Fire Device Showcase, Successful Case Studies, Regulatory Pathway, and an Investor Roundtable: Inside the VC Mindset.
Visit the Forum webpage for more details.
IPAC-RS Roundtable Webinar Series
In 2021, IPAC-RS launched a webinar series presented by SMEs in the pharmaceutical sciences, which enabled attendees the opportunity to learn about the latest research and regulatory trends. See the IPAC-RS Roundtables webpage for links to presentations and recordings for the webinars held in 2021 - 2025.
IPAC-RS September 2024 Workshop:
Inhaled Biologics: Preparing for a Future Beyond Small Molecules
This hybrid event brought together industry experts to discuss the key challenges facing developers of inhaled and nasal biologics.
Presentations and recordings are now available on the workshop webpage.
IPAC-RS representatives contributed to the planning of and presented at the CRCG Workshop: Navigating the Transition to Low Global Warming Potential Propellants held on December 4-5, 2024.
Ann Purrington (Kindeva) presented An Introduction to the IPAC-RS Scenarios - Transition to LGWP Propellants in MDIs: Proposed Pathways to U.S. FDA Approval and Richard Lostritto, Ph.D. (Consultant/IPAC-RS Science Advisor) and Helen Strickland (GSK) presented on Statistical Considerations for the In Vitro Comparisons of Critical Product Performance Attributes for an Approved MDI Product Transitioning to LGWP Propellant.
Podium presentations and recordings are now available at the weblink above.
News and Events
November 2026
SAVE THE DATES! IPAC-RS is collaborating with USP, US FDA, EDQM, and EPAG for an engaging two-day USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products to be held at USP on May 12-13, 2027.
Registration will open on December 1, 2026.
September 2026
IPAC-RS 2026 Nasal Innovation Forum
Wednesday - Thursday, September 16-17, 2026
This 1.5-day in-person event continued the discussions presented at the 2025 NIF and brought together industry leaders, academia, regulatory experts, and scientific pioneers, as they explored topics in: Patient Perspective (Keynote), Roadmap: From Discovery into the Clinic, Device Selection, Manufacturing Best Practices, Rapid Fire Device Showcase, Successful Case Studies, Regulatory Pathway, and an Investor Roundtable: Inside the VC Mindset.
Visit the Forum webpage for more details.
